What is the role of combination therapy for the treatment of cirrhosis?

Updated: Oct 15, 2020
  • Author: David C Wolf, MD, FACP, FACG, AGAF, FAASLD; Chief Editor: BS Anand, MD  more...
  • Print


According to an analysis of data from the TURQUOISE-II study, presented in October 2014 at the Annual Scientific Meeting of the American College of Gastroenterology (ACG), treatment with the combination of the protease inhibitor ABT-450 boosted with ritonavir, the NS5A inhibitor ombitasvir, and the non-nucleoside polymerase inhibitor dasabuvir plus ribavirin (3D + RBV) improved measures of liver function at 12 weeks in hepatitis C patients with cirrhosis. [58]

Highly significant improvements from baseline were seen at 12 weeks for the liver enzymes alanine aminotransferase, aspartate aminotransferase, and gamma-glutamyl transferase. [58]  Among patients with elevated transaminase levels at baseline, levels normalized after 12 weeks in 70-90% of cases. Highly significant improvements were also observed in conjugated bilirubin and albumin levels and in prothrombin time at 12 weeks.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!